Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
emb-02
- Development stage
- Unknown
- Lead developer
- EpimAb Biotherapeutics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
EMB-02 is a bispecific antibody developed by EpimAb Biotherapeutics that targets two immune checkpoint proteins, programmed cell death protein 1 (PD-1) and lymphocyte activation gene 3 (LAG-3, also known as CD223). It is designed to enhance anti-tumor immune responses by simultaneously inhibiting both PD-1 and LAG-3 pathways on T cells. This dual blockade aims to overcome resistance seen with standard anti-PD-1 monotherapies and stimulate T cell activity against tumors. EMB-02 is based on EpimAb’s proprietary FIT-Ig technology platform for generating bispecific antibodies with improved properties. The drug has shown strong anti-tumor activity in preclinical models resistant to standard therapies and is being evaluated in clinical trials for advanced solid tumors[1][2][3][4][5].
- Other names
- EMB 02EMB02EMB-02
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on emb-02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on emb-02.